Stada Ranibizumab Deal Doesn’t Change Coherus’ Aspirations

Coherus Looking To Refile By End Of Year

 
• By Dean Rudge
  
Eye
Coherus has high hopes for the biosimilar ophthalmology market in the US • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products